Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Poggio

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Contributions to Nephrology|January 1, 1984
Bicarbonate dialysis. Long-term results on vascular stability and dialysis tolerance of single pass and recirculating therapyA Salvadeo, A Cantaluppi, S Segagni, et al.
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association|January 1, 1983
Respiratory response of acetate dialysis and bicarbonate dialysisA Salvadeo, G Pezzagno, S Segagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debateF Poggio, M Tagliamento, M Ceppi, et al.
Breast (Edinburgh, Scotland)|April 1, 2017
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysisF Poggio, M Ceppi, M Lambertini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studiesM Lambertini, M Ceppi, F Poggio, et al.
ESMO Open|January 7, 2026
Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trialsR Borea, E Blondeaux, L Carmisciano, et al.
ESMO Open|January 22, 2025
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real worldE Blondeaux, L Boni, G Chilà, et al.
ESMO Open|February 18, 2021
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)C De Angelis, D Bruzzese, A Bernardo, et al.
ESMO Open|April 30, 2021
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054]C De Angelis, D Bruzzese, A Bernardo, et al.
ESMO Open|August 9, 2024
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trialF Poggio, E Blondeaux, M Tagliamento, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Contributions to Nephrology|January 1, 1984
Bicarbonate dialysis. Long-term results on vascular stability and dialysis tolerance of single pass and recirculating therapyA Salvadeo, A Cantaluppi, S Segagni, et al.
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association|January 1, 1983
Respiratory response of acetate dialysis and bicarbonate dialysisA Salvadeo, G Pezzagno, S Segagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debateF Poggio, M Tagliamento, M Ceppi, et al.
Breast (Edinburgh, Scotland)|April 1, 2017
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysisF Poggio, M Ceppi, M Lambertini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studiesM Lambertini, M Ceppi, F Poggio, et al.
ESMO Open|January 7, 2026
Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trialsR Borea, E Blondeaux, L Carmisciano, et al.
ESMO Open|January 22, 2025
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real worldE Blondeaux, L Boni, G Chilà, et al.
ESMO Open|February 18, 2021
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)C De Angelis, D Bruzzese, A Bernardo, et al.
ESMO Open|April 30, 2021
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054]C De Angelis, D Bruzzese, A Bernardo, et al.
ESMO Open|August 9, 2024
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trialF Poggio, E Blondeaux, M Tagliamento, et al.
Pageof 6